IART

$9.10

Post-MarketAs of Mar 17, 8:00 PM UTC

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.10
Potential Upside
5%
Whystock Fair Value$9.55
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Sur...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$709.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-39.90%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.19

Recent News

Zacks
Mar 16, 2026

Should You Continue to Hold Integra Stock in Your Portfolio Now?

IART faces macro headwinds and tight liquidity, but strong demand in its Codman Specialty Surgical unit and expanding international launches could support growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 12, 2026

Why Integra LifeSciences (IART) Shares Are Sliding Today

Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 5.7% in the afternoon session after Citigroup lowered its price target on the stock from $11.00 to $9.00 and maintained its 'Sell' rating.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 9, 2026

3 Profitable Stocks with Open Questions

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 2, 2026

Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up

IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.